| 46952-8 |
Fluticasone propionate |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Fluticasone propionate [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
46952-8 |
|
|
|
|
Both |
|
|
|
0 |
Fluticasone Prop Ur-mCnc |
|
|
|
N |
|
Cutivate; DRUG/TOXICOLOGY; Drugs; Flonase; Flovent; Level; Mass concentration; Point in time; Propanoic acid; Propioate; Propioic acid; Propionic acid; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.42 |
2.19 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
| 46953-6 |
Megestrol acetate |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Megestrol acetate [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
46953-6 |
|
|
|
|
Both |
|
|
|
0 |
Megestrol Acetate Ur-mCnc |
|
|
|
N |
|
Acetic acid; DRUG/TOXICOLOGY; Drugs; Ethanoate; Ethanoic acid; Level; Mass concentration; Megace; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.42 |
2.19 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
| 46954-4 |
Methylprednisolone |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Methylprednisolone [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
46954-4 |
|
|
|
|
Both |
|
|
|
0 |
Me-prednisolone Ur-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; MeP; Me-prednisolone; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.42 |
2.19 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
| 46955-1 |
prednisoLONE |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
prednisoLONE [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
46955-1 |
|
|
|
|
Both |
|
|
|
0 |
prednisoLONE Ur-mCnc |
|
|
|
N |
|
c424; Deltasone; Depo-Medrol; DRUG/TOXICOLOGY; Drugs; Kenalog; Level; Mass concentration; Medrol; Point in time; QNT; Quan; Quant; Quantitative; Random; Solu-Medrol; UA; UR; Urn |
2.42 |
2.19 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
| 46956-9 |
predniSONE |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
predniSONE [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
46956-9 |
|
|
|
|
Both |
|
|
|
0 |
predniSONE Ur-mCnc |
|
|
|
N |
|
C254; Cortan; Deltasone; DRUG/TOXICOLOGY; Drugs; Level; Liquid Pred; Mass concentration; Meticorten; Orasone; Panasol-S; Point in time; Prednicen-M; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.42 |
2.19 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 46957-7 |
Triamcinolone |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Triamcinolone [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
46957-7 |
|
|
|
|
Both |
|
|
|
0 |
Triamcinolone Ur-mCnc |
|
|
|
N |
|
Aristocort; Atolone; DRUG/TOXICOLOGY; Drugs; Kenacort; Kenalog; Level; Mass concentration; Mycolog II; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.42 |
2.19 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
| 46958-5 |
Triamcinolone acetonide |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Triamcinolone acetonide [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
46958-5 |
|
|
|
|
Both |
|
|
|
0 |
Triamcinolone Aceto Ur-mCnc |
|
|
|
N |
|
Aristocort; Atolone; Azmacort; DRUG/TOXICOLOGY; Drugs; Kenacort; Kenalog; Level; Mass concentration; Mycolog II; Nasacort; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.42 |
2.19 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
| 46959-3 |
Synthetic glucocorticoid panel |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Synthetic glucocorticoid panel [Mass/volume] - Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CHEM |
|
46959-3 |
|
|
|
|
Order |
|
|
|
0 |
Syn Glucocorticoid Pnl Ur-mCnc |
|
|
|
N |
|
Chemistry; Level; Mass concentration; Pan; PANEL.CHEMISTRY; Panl; Pnl; Point in time; QNT; Quan; Quant; Quantitative; Random; Syn Glucocorticoid Pnl; UA; UR; Urn |
2.42 |
2.19 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 4696-1 |
HLA-A19 |
PrThr |
Bld/Tiss |
Pt |
Ord |
|
|
ACTIVE |
HLA-A19 [Presence] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4696-1 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-A19 Ql |
|
|
|
|
|
Blood; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld' to 'Bld/Tiss' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 46960-1 |
TCR alpha beta Ag |
PrThr |
Tiss |
Pt |
Ord |
Immune stain |
|
ACTIVE |
TCR alpha beta Ag [Presence] in Tissue by Immune stain |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CELLMARK |
|
46960-1 |
|
Immune stain |
|
|
Both |
|
|
|
0 |
TCR A-B Ag Tiss Ql ImStn |
|
|
|
N |
|
Alfa; Antigen; Antigens; B; CELL MARKERS; IHC; Imm; Immunohistochemical stain; Immunostain; ImStn; Imun; Imune; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; St; Stains; Stn; TCR A-B; Tissue; Tissue, unspecified |
2.56 |
2.19 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 46961-9 |
TCR gamma delta Ag |
PrThr |
Tiss |
Pt |
Ord |
Immune stain |
|
ACTIVE |
TCR gamma delta Ag [Presence] in Tissue by Immune stain |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CELLMARK |
|
46961-9 |
|
Immune stain |
|
|
Both |
|
|
|
0 |
TCR G-D Ag Tiss Ql ImStn |
|
|
|
N |
|
Antigen; Antigens; CELL MARKERS; IHC; Imm; Immunohistochemical stain; Immunostain; ImStn; Imun; Imune; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; St; Stains; Stn; TCR G-D; Tissue; Tissue, unspecified |
2.56 |
2.19 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 46962-7 |
Vasoactive intestinal peptide Ag |
PrThr |
Tiss |
Pt |
Ord |
Immune stain |
|
ACTIVE |
Vasoactive intestinal peptide Ag [Presence] in Tissue by Immune stain |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PATH |
|
46962-7 |
|
Immune stain |
|
|
Both |
|
|
|
0 |
VIP Ag Tiss Ql ImStn |
|
|
|
N |
|
Antigen; Antigens; IHC; Imm; Immunohistochemical stain; Immunostain; ImStn; Imun; Imune; Intest; Intestine; Ordinal; PATHOLOGY; Pept; Point in time; PR; QL; Qual; Qualitative; Random; Screen; St; Stains; Stn; Tissue; Tissue, unspecified; Vaso; Vasoactive intestinal polypeptide; VIP |
2.56 |
2.19 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 46963-5 |
Tube number |
ID |
Ser/Plas/Bld |
Pt |
Nom |
|
|
ACTIVE |
Tube number of Serum, Plasma or Blood |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SPEC |
|
46963-5 |
|
|
|
|
Observation |
|
|
|
0 |
Tube # SerPlBld |
|
|
|
N |
|
Blood; Ident; Identifier; No; Nominal; Num; Pl; PlasBld; Plasma; Plsm; Point in time; Random; SerP; SerPl; SerPlas; SerPlBld; Serum; Serum or plasma; Serum, plasma or whole blood; SPEC; SR; Tube #; WB; Whole blood |
2.73 |
2.19 |
|
|
|
|
|
|
|
|
|
|
Updated System from "Bld" to "Ser/Plas/Bld" so this term can be used to represent the tube number for whole blood, serum or plasma specimen tubes. |
0 |
| 46964-3 |
Cryptococcus sp Ag |
PrThr |
CSF |
Pt |
Ord |
LA |
|
ACTIVE |
Cryptococcus sp Ag [Presence] in Cerebral spinal fluid by Latex agglutination |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
46964-3 |
|
LA |
|
|
Both |
|
|
|
0 |
Cryptoc Ag CSF Ql LA |
|
|
|
N |
|
Antigen; Antigens; Cerebral spinal fluid; Cerebrospinal Fl; Crypt; Crypto; Cryptococcal; Cryptococcosis; Cryptococcosus; ID; Infectious Disease; InfectiousDisease; LAT; Latex agglutination; Microbiology; Neuro; Neurology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; species; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; spp |
2.73 |
2.19 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 46965-0 |
MCOLN1 gene targeted mutation analysis |
Find |
Bld/Tiss |
Pt |
Doc |
Molgen |
|
ACTIVE |
MCOLN1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MOLPATH.MUT |
|
46965-0 |
|
Molgen |
|
|
Both |
|
|
|
0 |
MCOLN1 gene Mut Anl Bld/T |
|
|
|
N |
|
Blood; Document; Finding; Findings; Genetics; Heredity; Heritable; Inherited; MG-2; ML4; MLIV; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; MST080; MSTP080; mucolipidin; Mucolipidosis type IV protein; mucolipin 1; Mut; Mut Anl; Mutations; PCR; Point in time; Random; Tissue; Tissue, unspecified; TRPML1; TRP-ML1; TRPM-L1; WB; Whole blood; Whole blood or Tissue |
2.73 |
2.19 |
|
|
|
|
|
|
|
|
|
|
Based on LOINC Committee review (June 2016), "targeted" was added to the Component to clarify that this test is looking for a specific set of mutations as described in the LOINC User Guide under the Molecular Genetics section.; Based on LOINC Committee review (June 2019), updated the Property from "Prid" to "Find" and Scale from "Nar" to "Doc" to align with the current LOINC model for naming collections of information reported in narrative and/or structured formats. |
0 |
| 46966-8 |
Cells.CD69 |
NCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
CD69 cells [#/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
10*3/uL |
|
|
|
|
|
|
CELLMARK |
|
46966-8 |
|
|
|
|
Both |
|
|
|
0 |
CD69 Cells # Bld |
|
|
|
N |
|
#; ABS; absolute; absolutes; Activation inducer molecule; AIM; Blood; CD69 Cells; Cell; CELL MARKERS; Cellularity; Cnt; Count; Count/volume; CT; EA 1; gp34/28; Leu23; Leu-23; MLR3; Number concentration; Number Concentration (count/vol); Point in time; QNT; Quan; Quant; Quantitative; Random; VEA; Very early activation; WB; Whole blood |
2.7 |
2.19 |
|
|
|
|
|
|
|
/uL |
|
|
|
0 |
| 46967-6 |
Cells.CD40 |
NCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
CD40 cells [#/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
10*3/uL |
|
|
|
|
|
|
CELLMARK |
|
46967-6 |
|
|
|
|
Both |
|
|
|
0 |
CD40 Cells # Bld |
|
|
|
N |
|
#; ABS; absolute; absolutes; Blood; Bp50; CD40 Cells; Cell; CELL MARKERS; Cellularity; Cnt; Count; Count/volume; CT; Number concentration; Number Concentration (count/vol); Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.7 |
2.19 |
|
|
|
|
|
|
|
/uL |
|
|
|
0 |
| 46968-4 |
Cells.CD122 |
NCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
CD122 cells [#/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
10*3/uL |
|
|
|
|
|
|
CELLMARK |
|
46968-4 |
|
|
|
|
Both |
|
|
|
0 |
CD122 Cells # Bld |
|
|
|
N |
|
#; ABS; absolute; absolutes; Blood; CD122 Cells; Cell; CELL MARKERS; Cellularity; Cnt; Count; Count/volume; CT; IL-2Rbeta; Interleukin 2 receptor beta chain; Number concentration; Number Concentration (count/vol); Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.7 |
2.19 |
|
|
|
|
|
|
|
/uL |
|
|
|
0 |
| 46969-2 |
Asialoganglioside GM1 Ab.IgG |
Titr |
Ser |
Pt |
SemiQn |
IA |
|
ACTIVE |
Asialoganglioside GM1 IgG Ab [Titer] in Serum by Immunoassay |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
SERO |
|
46969-2 |
|
IA |
|
|
Both |
|
|
|
0 |
GM1 Asialo IgG Titr Ser IA |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Asialo Gm1; AsialoGM1; Autoantibodies; Autoantibody; Dilution factor; Dilution Factor (Titer); EIA; ELFA; ELISA; Enzyme immunoassay; Ganglioside asialo; GM1 Asialo; IAA; Immune globulin G; Immunoglobulin G; MEIA; Monoasialoganglioside; Point in time; Random; Serology; Serum; SmQn; SR; SUDS; Titer; Titered; Titre; Ttr |
2.75 |
2.19 |
|
|
|
|
|
|
|
{titer} |
|
|
The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 4697-9 |
HLA-A33(19) |
PrThr |
Bld/Tiss^Donor |
Pt |
Ord |
|
|
ACTIVE |
HLA-A33(19) [Presence] in Donor |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4697-9 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-A33(19) Donr Ql |
|
|
|
|
|
Blood; Donr; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld^donor' to 'Bld/Tiss^donor' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 46970-0 |
BK virus DNA |
PrThr |
CSF |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
BK virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
Not detected |
|
|
|
|
|
MICRO |
|
46970-0 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
BKV DNA CSF Ql NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; BKV; Cerebral spinal fluid; Cerebrospinal Fl; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Neuro; Neurology; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Strand Displacement Amplification; TMA; Transcription mediated amplification |
2.63 |
2.19 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 46971-8 |
HYDROmorphone.free |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
HYDROmorphone Free [Mass/volume] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
46971-8 |
|
Confirm |
|
|
Both |
|
|
|
0 |
HYDROmorphone Free Ur Cfm-mCnc |
|
|
|
N |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; Dihydromorphinone; Dilaudid; DRUG/TOXICOLOGY; Drugs; FR; GCMS; Hydromorphinone; HYDROmorphone Free; LC/MS/MS; Level; Mass concentration; Non-protein bound; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.7 |
2.19 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 46972-6 |
6-Monoacetylmorphine.free |
MCnc |
Ser/Plas |
Pt |
Qn |
Confirm |
|
DEPRECATED |
Deprecated 6-monoacetylmorphine free [Mass/volume] in Serum or Plasma by Confirm method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
46972-6 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Deprecated 6MAM Free SerPl Cfm-mCnc |
|
|
|
N |
|
6 MAM; 6 mono acetyl morphine; 6-acetylmorphine; 6MAM; 6MAM Free; Acetylmorphine; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; FR; GCMS; Heroin metabolite; LC/MS/MS; Level; MAM; Mass concentration; Non-protein bound; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.19 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 46973-4 |
oxyCODONE.free |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
oxyCODONE Free [Mass/volume] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
46973-4 |
|
Confirm |
|
|
Both |
|
|
|
0 |
oxyCODONE Free Ur Cfm-mCnc |
|
|
|
N |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; FR; GCMS; LC/MS/MS; Level; Lortab; Mass concentration; Non-protein bound; oxyCODONE Free; OxyContin; Percocet; Percodan; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn; Vicodin |
2.73 |
2.19 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 46974-2 |
oxyMORphone.free |
MCnc |
Ser/Plas |
Pt |
Qn |
Confirm |
|
ACTIVE |
oxyMORphone Free [Mass/volume] in Serum or Plasma by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
46974-2 |
|
Confirm |
|
|
Both |
|
|
|
0 |
oxyMORphone Free SerPl Cfm-mCnc |
|
|
|
N |
|
14-Hydroxydihydromorphinone; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; FR; GCMS; LC/MS/MS; Level; Mass concentration; Non-protein bound; Numorphan; Numorphone; Opana; oxyMORphone Free; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
2.19 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
